Common questions about ACAM2000 (FAQ)
Q: How long after vaccination with ACAM2000 does protection begin?
A: According to official guidance, the peak immune response activity is described as typically occurring four weeks after the single dose of ACAM2000 is administered. The full immune response develops over this time period.
Q: How often do people need to get revaccinated with ACAM2000?
A: Revaccination is advised with a single booster dose every three years, but only for individuals who have an ongoing high occupational risk of exposure to orthopoxviruses. This regimen is described to help maintain immunity levels for specific high-risk groups.
Q: Can a person who is breastfeeding receive ACAM2000?
A: Official product information states that use is officially advised against for people who are breastfeeding. This is due to the risk of contact transmission of the live virus from the recipient to the infant until the vaccination site has completely healed.
Q: What special steps should be taken to prevent the virus from spreading to close contacts?
A: To help prevent transmission, the vaccination site must be covered with a loose gauze bandage secured with medical tape until the scab naturally falls off. Official guidance emphasizes washing hands with soap and water or an alcohol-based hand rub after any contact with the site or bandage.
Q: How long does the risk of spreading the virus last after ACAM2000 vaccination?
A: The risk of spreading the live virus lasts until the vaccination site is fully healed. This period lasts until the scab separates naturally and a new layer of skin has formed beneath it, a process that can take several weeks.
Q: How does the vaccine lesion need to be covered and cared for?
A: The site should be covered with a loose gauze bandage secured with tape. Regulatory documents indicate the bandage is typically changed at least every one to three days, or when it becomes wet. Guidance advises against the use of salves, ointments, or any occlusive bandage.
Q: Is the vaccination site supposed to be covered with a special type of dressing?
A: Regulatory documents recommend using a loose gauze bandage secured with medical tape. Guidance advises against the use of bandages that block air or cause the skin to soften, such as most adhesive strips, as proper covering is required for containment until the site is healed.
Q: Why does the package insert mention a risk of myocarditis and pericarditis?
A: Myocarditis (heart muscle inflammation) and pericarditis (inflammation of the heart lining) are included in the official documentation because they are serious adverse events that have been reported following vaccination. Regulatory documents mention these risks because they must be listed as a formal warning.
Q: Is ACAM2000 used for protection against any other viruses besides smallpox?
A: Yes. According to official information, ACAM2000 is used for active immunization against both smallpox and related orthopoxviruses, specifically including mpox (formerly monkeypox) disease.
Q: Does ACAM2000 interact with other vaccines, such as the flu or COVID-19 vaccine?
A: ACAM2000 must be separated from other live injectable vaccines by at least 28 days to avoid potential immune interference. Regulatory documents do not provide specific guidance on separation requirements for non-live (inactivated) vaccines.
Q: Is it possible to receive the ACAM2000 vaccine if I am HIV-positive?
A: No. Official guidance states that the vaccine is contraindicated (must not be given) for individuals with HIV or AIDS. As it is a live virus vaccine, it is prohibited in individuals with compromised immune systems.
Q: Is ACAM2000 considered a traditional 'shot' or is it administered differently?
A: ACAM2000 is administered differently than a traditional shot. It is given using a two-prong needle and the scarification technique, which involves making multiple shallow pricks in the superficial skin layers, and is not given via a typical injection route.
Q: Is it normal to get a blister or scab at the ACAM2000 vaccination site?
A: Yes, for a primary vaccination, a red bump forms that develops into a blister, then a pus-filled pustule, and finally forms a scab. This progression is described as the expected sign of a successful response.
Q: How long does the lesion or 'take' at the vaccination site usually last?
A: The full progression of the lesion, from its appearance to the point where the scab naturally separates, typically takes two to three weeks (14 to 21 days). A small, permanent scar usually remains after the site has fully healed.
Q: What is the biggest or most serious side effect people worry about with ACAM2000?
A: The most prominent serious risks documented in regulatory warnings are heart problems, specifically myocarditis and pericarditis, which are forms of heart inflammation. These are specifically noted for primary vaccine recipients and occur within the first month after vaccination.
Q: Are there any long-term side effects known to be associated with ACAM2000?
A: Official product information states that the long-term outcome of certain serious adverse events, such as myocarditis and pericarditis following ACAM2000 vaccination, is currently unknown and subject to ongoing monitoring.
Q: Is fever a common reaction after receiving ACAM2000?
A: Yes. Regulatory documents list fever as a very common systemic adverse reaction following ACAM2000 administration. Other common reactions include headache, fatigue, and muscle aches.
Q: What does it mean if the vaccination site doesn't develop a blister or scab?
A: If the site does not develop the expected major reaction—a pustule followed by a scab—by around day six or eight, it is called an 'equivocal reaction' or 'non-take.' This outcome is interpreted as a failure of the vaccination, which may require revaccination.
Q: Who is considered 'at high risk' for infection and therefore eligible for ACAM2000?
A: According to public health guidance, 'high risk' typically refers to individuals whose work involves handling the virus (laboratory personnel), those who treat patients with the infection, or military personnel in a specific preparedness context. Eligibility is determined based on criteria established by official public health authorities.
Q: Is ACAM2000 recommended for children or people under 18?
A: The vaccine is not generally recommended for people under 18 years of age. Its use in children is conditional upon determination of an imminent, high risk of exposure and is strictly contraindicated for children under one year old.
Q: What are the risks of accidental spread of the virus to the eye (ocular vaccinia)?
A: Ocular complications are a serious risk listed in regulatory safety information. Accidental infection of the eye with the vaccinia virus can cause irritation and damage to the cornea, and has been documented to cause vision loss in rare cases.
Q: What should be done with the scab when it falls off the vaccination site?
A: The detached scab is considered biohazardous material because it contains the live virus. Official guidance indicates that the detached scab should be placed in a sealed plastic bag with a small amount of bleach before being discarded.
Q: Is it safe to exercise or swim after receiving ACAM2000?
A: Guidance suggests the site be covered with a waterproof bandage during bathing or showering. Physical activities that could cause the bandage to come off or irritate the area are advised to be avoided until the site has healed.
Q: What is the difference between a 'major take' and an 'equivocal reaction'?
A: A 'major take' is the formation of a pustule followed by a scab, which is the expected physical sign indicating the initial success of the vaccination. An 'equivocal reaction' is any minor reaction that is not a major take and is classified as a vaccination failure.
Q: Can ACAM2000 be administered at the same time as other live vaccines?
A: No. According to official guidance, ACAM2000 and any other live injectable vaccines should not be given simultaneously and must be separated by at least 28 days. This separation is advised to prevent potential immune interference and confusion regarding potential side effects.
Q: What kind of studies have been done to confirm ACAM2000's effectiveness?
A: Studies confirm the vaccine’s effectiveness primarily through non-inferiority trials, which show that the immune response to ACAM2000 is comparable to the older smallpox vaccine. Efficacy is also supported by studies in animal models and by observational data.
Q: What should I do if I accidentally touch the vaccination site?
A: Because the site is infectious, official guidance recommends immediate washing of hands with soap and warm water or an alcohol-based hand rub after any direct or suspected contact with the vaccination site, the bandage, or any items that may have touched it.
Q: Why are there special warnings for people who use steroid eye drops?
A: Official documentation notes caution for those using topical steroids for eye conditions. This is because they are listed as a risk factor for serious vaccine side effects, including complications like ocular vaccinia, from accidental spread.
Q: Are there any specific allergies or sensitivities that prevent someone from receiving ACAM2000?
A: Yes. Use is strictly contraindicated if there is a known severe allergy to the vaccine or any of its components. These components include the antibiotics neomycin and polymixin B, as well as egg protein.
Q: Can a history of high blood pressure or high cholesterol affect the safety of ACAM2000?
A: Official guidance states that individuals with three or more risk factors for ischemic coronary disease, such as a history of high blood pressure (hypertension) or high cholesterol (hypercholesterolemia), are determined to be at increased risk of cardiovascular adverse events, according to official documents.
Q: Can the vaccinia virus from the vaccine contaminate clothing or towels?
A: Yes. The live vaccinia virus can be passed to others indirectly. This can happen through close contact with contaminated items such as towels, bedding, or clothing that have touched the vaccination site or any drainage from the lesion.
Q: Is ACAM2000 still effective if a person has a minor, non-pustular reaction?
A: No. Official documents state that a major reaction, characterized by the formation of a pustule, is necessary for success. A minor or non-pustular reaction is classified as an equivocal reaction (vaccination failure), meaning protective immunity was not acquired.
Q: Can a person get ACAM2000 if they have a minor skin condition like contact dermatitis?
A: Official guidance states that skin problems, including contact dermatitis, are generally viewed as a contraindication. This is due to the increased risk of serious complications, particularly the uncontrolled spread of the virus.
Q: What evidence is there about the durability or long-term strength of the protection from ACAM2000?
A: While the adaptive immune response establishes long-lasting memory cells, the exact duration of protection is not definitively established. Official guidance for exposed professionals suggests revaccination every three years to help maintain immunity levels.
Q: What is 'Post-vaccinial Encephalitis' and what is the risk?
A: Post-vaccinial encephalitis is inflammation of the brain or spinal cord, which is listed as a serious adverse event. Regulatory data show the reported incidence rate is extremely rare, estimated at approximately 1.37 cases per million primary vaccinations.
